Soluble BTN2A1 as a potential predictive biomarker of immune checkpoint inhibitor efficacy in advanced non-small cell lung cancer (NSCLC).

被引：0
|
作者：
Rochigneux, Philippe
Chretien, Anne Sophie
Rossille, Delphine
Chanez, Brice
Billon, Emilien
Fattori, Stephane
Corre, Romain
Pakradouni, Jihane
Goncalves, Anthony
Fest, Thierry
Madroszyk, Anne
Olive, Daniel
机构：
[1] Inst Paoli Calmettes, CRCM U1068, Marseille, France
[2] CRCM, Marseille, France
[3] Univ Hosp Rennes, Rennes, France
[4] Inst Paoli Calmette, Marseille, France
[5] Rennes Univ Hosp, Rennes, France
[6] Inst Paoli Calmettes, Dept Clin Res & Innovat, Marseille, France
[7] Aix Marseille Univ, Inst Paoli Calmettes, Dept Med Oncol, CRCM,CNRS,INSERM, Marseille, France
[8] Inst Paoli Calmettes CRCM U1068, Marseille, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9561
引用
收藏
页数：2
相关论文
共 50 条
  • [21] PTPRD: A Positive Predictive Biomarker for Immune Checkpoint Blockade Therapy in Non-Small Cell Lung Cancer
    Shen, J.
    Zhou, H.
    Liu, J.
    Zhang, Y.
    Zhou, T.
    Hong, S.
    Zhao, Y.
    Yang, Y.
    Zhao, H.
    Huang, Y.
    Fang, W.
    Zhang, L.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S335 - S336
  • [22] Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer
    Assi, Hazem I.
    Kamphorst, Alice O.
    Moukalled, Nour M.
    Ramalingam, Suresh S.
    CANCER, 2018, 124 (02) : 248 - 261
  • [23] Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC)
    Jeanson, Arnaud
    Tomasini, Pascale
    Souquet-Bressand, Maxime
    Brandone, Nicolas
    Boucekine, Mohamed
    Grangeon, Mathieu
    Chaleat, Solene
    Khobta, Natalyia
    Milia, Julie
    Mhanna, Laurent
    Greillier, Laurent
    Biemar, Julie
    Nanni, Isabelle
    Ouafik, L'houcine
    Garcia, Stephane
    Mazieres, Julien
    Barlesi, Fabrice
    Mascaux, Celine
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (06) : 1095 - 1101
  • [24] Efficacy and safety of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer (NSCLC): a systematic literature review
    Wagner, Gernot
    Stollenwerk, Hannah Karolina
    Klerings, Irma
    Pecherstorfer, Martin
    Gartlehner, Gerald
    Singer, Josef
    ONCOIMMUNOLOGY, 2020, 9 (01):
  • [25] Novel immune checkpoint inhibitor strategies in advanced non-small cell lung cancer: towards biomarker-driven therapies?
    Muntinghe-Wagenaar, M. Benthe
    Hiltermann, T. Jeroen N.
    TRANSLATIONAL LUNG CANCER RESEARCH, 2025, 14 (02) : 328 - 333
  • [26] HLA-A2 Status and Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients
    Mezquita, Laura
    Charrier, Melinda
    Auclin, Edouard
    Dupraz, Louise
    Remon, Jordi
    Planchard, David
    Gion, Maria
    Lahmar, Jihene
    Gazzah, Annas
    Adam, Julien
    Chaput, Nathalie
    Besse, Benjamin
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1316 - S1316
  • [27] RE: Smoking History as a Potential Predictor of Immune Checkpoint Inhibitor Efficacy in Metastatic Non-Small Cell Lung Cancer
    Hopkins, Ashley M.
    Kichenadasse, Ganessan
    Logan, Jessica M.
    Rowland, Andrew
    Sorich, Michael J.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2022, 114 (03): : 475 - 476
  • [28] Clinically relevant prognostic and predictive markers for immune-checkpoint-inhibitor (ICI) therapy in non-small cell lung cancer (NSCLC)
    Brueckl, Wolfgang M.
    Ficker, Joachim H.
    Zeitler, Gloria
    BMC CANCER, 2020, 20 (01)
  • [29] Clinically relevant prognostic and predictive markers for immune-checkpoint-inhibitor (ICI) therapy in non-small cell lung cancer (NSCLC)
    Wolfgang M. Brueckl
    Joachim H. Ficker
    Gloria Zeitler
    BMC Cancer, 20
  • [30] Is checkpoint inhibitor pneumonitis underreported in patients with advanced non-small cell lung cancer (NSCLC) on PD-1 inhibitor monotherapy?
    Spieler, Benjamin Oren
    Lopes, Gilberto
    Dal Pra, Alan
    Diwanji, Tejan
    Yechieli, Raphael
    Freedman, Laura M.
    Mihaylov, Ivaylo
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345